Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

DANIPHARM A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   0.7% 1.4% 0.6% 0.6% 0.5% 0.5% 9.5% 9.3%   Credit score (0-100)   95 80 97 97 99 99 25 6   Credit rating   A BBB A A AA AA B B   Credit limit (kDKK)   3,470.9 326.4 3,524.1 3,698.7 4,663.4 5,169.6 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Net sales   0 92,642 0 0 0 0 0 0   Gross profit   35,699 42,946 31,639 29,395 34,935 35,152 0.0 0.0   EBITDA   14,468 22,429 9,588 6,903 11,519 10,356 0.0 0.0   EBIT   12,999 20,703 7,402 4,569 9,217 8,056 0.0 0.0   Pre-tax profit (PTP)   13,117.2 20,927.9 7,393.5 3,772.5 10,498.7 6,905.8 0.0 0.0   Net earnings   10,231.4 16,324.5 5,767.4 2,944.0 8,190.7 5,390.8 0.0 0.0   Pre-tax profit without non-rec. items   13,117 20,928 7,393 3,772 10,499 6,906 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Tangible assets total   18,188 17,473 18,659 17,072 14,963 13,006 0.0 0.0   Shareholders equity total   24,833 21,157 26,924 29,869 36,059 41,450 40,950 40,950   Interest-bearing liabilities   356 0.6 28,744 28,249 24,207 25,312 0.0 0.0   Balance sheet total (assets)   36,363 33,983 68,942 73,178 78,307 87,076 40,950 40,950   Net Debt   -316 -1,057 28,596 27,254 24,207 25,312 -40,950 -40,950     See the entire balance sheet 1000.0 Volume  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Net sales   0 92,642 0 0 0 0 0 0   Net sales growth   0.0% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   35,699 42,946 31,639 29,395 34,935 35,152 0.0 0.0   Gross profit growth   -3.6% 20.3% -26.3% -7.1% 18.8% 0.6% -100.0% 0.0%   Employees   22 21 22 25 26 28 0 0   Employee growth %   -15.4% -4.5% 4.8% 13.6% 4.0% 7.7% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   36,363 33,983 68,942 73,178 78,307 87,076 40,950 40,950   Balance sheet change%   -43.9% -6.5% 102.9% 6.1% 7.0% 11.2% -53.0% 0.0%   Added value   14,468.2 22,428.9 9,587.9 6,903.4 11,551.1 10,356.4 0.0 0.0   Added value %   0.0% 24.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -2,682 -2,440 -1,000 -3,921 -4,411 -4,256 -13,006 0   Net sales trend   0.0 0.0 -1.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A EBITDA %   0.0% 24.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 22.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   36.4% 48.2% 23.4% 15.5% 26.4% 22.9% 0.0% 0.0%   Net Earnings %   0.0% 17.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 19.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 22.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   26.2% 59.6% 15.0% 7.4% 15.1% 10.9% 0.0% 0.0%   ROI %   32.6% 86.3% 19.3% 9.0% 18.7% 13.8% 0.0% 0.0%   ROE %   27.1% 71.0% 24.0% 10.4% 24.8% 13.9% 0.0% 0.0%   1000.0 Solidity  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Equity ratio %   68.3% 65.8% 39.2% 40.8% 46.0% 47.6% 100.0% 100.0%   Relative indebtedness %   0.0% 12.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 11.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -2.2% -4.7% 298.3% 394.8% 210.2% 244.4% 0.0% 0.0%   Gearing %   1.4% 0.0% 106.8% 94.6% 67.1% 61.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   7.4% 20.9% 2.2% 5.3% 3.5% 8.4% 0.0% 0.0%   1000.0 Liquidity  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Quick Ratio   1.0 0.8 1.0 1.2 1.3 1.3 0.0 0.0   Current Ratio   1.7 1.4 1.4 1.5 1.6 1.7 0.0 0.0   Cash and cash equivalent   672.2 1,057.9 148.2 995.3 0.1 0.1 0.0 0.0   1000.0 Capital use efficiency  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Trade debtors turnover (days)   0.0 12.4 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 24.2 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 17.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   7,571.0 4,973.1 14,560.1 17,804.0 22,897.8 30,289.2 0.0 0.0   Net working capital %   0.0% 5.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Net sales / employee   0 4,412 0 0 0 0 0 0   Added value / employee   658 1,068 436 276 444 370 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   658 1,068 436 276 443 370 0 0   EBIT / employee   591 986 336 183 354 288 0 0   Net earnings / employee   465 777 262 118 315 193 0 0